Leap Therapeutics Inc (NASDAQ:LPTX) has a beta value of -0.22 and has seen 47.46 million shares traded in the recent trading session. The company, currently valued at $16.45M, closed the recent trade at $2160000.0 per share which meant it gained $2159999.62 on the day or 47455546% during that session. The LPTX stock price is 100.0% off its 52-week high price of $4.79 and 100.0% above the 52-week low of $0.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.32 million shares traded. The 3-month trading volume is 2.16 million shares.
The consensus among analysts is that Leap Therapeutics Inc (LPTX) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Over the past 30 days, the shares of Leap Therapeutics Inc (NASDAQ:LPTX) have changed 9.85%. Short interest in the company has seen 1.54 million shares shorted with days to cover at 4.59.
Wall Street analysts have a consensus price target for the stock at $5.5, which means that the shares’ value could drop -39272627.27% from the levels at last check today.. The projected low price target is $5.5 while the price target rests at a high of $5.5. In that case, then, we find that the latest price level in today’s session is 100.0% off the targeted high while a plunge would see the stock lose 100.0% from the levels at last check today..
Leap Therapeutics Inc (LPTX) estimates and forecasts
The company’s shares have lost -87.23% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 34.28% over the past 5 years. Earnings growth for 2025 is a modest 38.67% while over the next 5 years, the company’s earnings are expected to increase by 32.77%.
LPTX Dividends
Leap Therapeutics Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Insiders own 16.20% of the company shares, while shares held by institutions stand at 29.17% with a share float percentage of 34.81%. Investors are also buoyed by the number of investors in a company, with Leap Therapeutics Inc having a total of 50.0 institutions that hold shares in the company. The top two institutional holders are BALYASNY ASSET MANAGEMENT L.P. with over 3.1 million shares worth more than $6.08 million. As of 2024-06-30, BALYASNY ASSET MANAGEMENT L.P. held 7.9238% of shares outstanding.
The other major institutional holder is SAMSARA BIOCAPITAL, LLC, with the holding of over 2.44 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.79 million and represent 6.2428% of shares outstanding.
